# Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

> **NCT01181050** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 63 (actual)

## Conditions studied

- Inflammation
- Rheumatoid Arthritis

## Interventions

- **DRUG:** NNC0142-0002
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01181050
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2016-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181050, "Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01181050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*